Investigation on a Freeze-Drying Process for Long-Term Stability of mRNA-LNPs
Vaccines · 06.03.2026 · 14 (3) · 242
DOI: 10.3390/vaccines14030242 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 06.03.2026. Verfasst von M D Faizul Hussain Khan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Viral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montreal, QC H2X 1Y4, Canada. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Sciences and Engineering Research Council of Canada, Canada Research Chairs, Canada Biomedical Research Fund.
Abstract (Originalsprache)
Background
Thermostability remains a key bottleneck for equitable access to mRNA-LNPs vaccines, mainly due to cold-chain requirements. Objectives and methods: Here, we optimized freeze-drying formulations by screening excipients (sugars, sugar alcohols, and proteins) and buffers to preserve mRNA-LNPs as solid formulations under ambient and refrigerated conditions. Physicochemical properties (size, polydispersity index [PDI], and encapsulation efficiency [EE]) and functional integrity, assessed by fluorescence-based in vitro transfection assays, were evaluated during long-term storage of up to six months.
Results
Preliminary screening identified 20% sucrose and trehalose with Tris or histidine buffers as optimal for preserving physicochemical properties during freeze-drying, including high encapsulation efficiency (>90%), particle size (~200 nm), and low polydispersity (PDI < 0.2). Mannitol, gelatin, and PBS-based buffers showed adverse effects. At 4 °C, formulations F1–F3 maintained physicochemical stability and functional transfection activity for up to four months. In contrast, 20 °C storage caused progressive destabilization, with increased size, PDI, and encapsulation loss (>60% by six months). Among all formulations, 20% sucrose with 5 mM Tris (F1) showed the most robust preservation of physicochemical integrity and in vitro transfection efficiency under refrigerated and ambient conditions.
Conclusions
Sugars outperformed sugar alcohols and gelatin as cryoprotectants. All formulations were stable, including functionally active at 4 °C for up to four months, while a sucrose/Tris formulation retained acceptable stability at 20 °C. Overall, the results demonstrate the feasibility of storing mRNA drug products as solid formulations at non-freezing temperatures.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Viral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montreal, QC H2X 1Y4, Canada.
- Department of Bioengineering, McGill University, Montreal, QC H3A 0E9, Canada.
ORCID-Profile: M D Faizul Hussain Khan, Ayyappasamy Sudalaiyadum Perumal, Amine A Kamen
Förderung
- Natural Sciences and Engineering Research Council of Canada
- Canada Research Chairs
- Canada Biomedical Research Fund
- Natural Sciences and Engineering Research Council
- Canada Research Chair
Zitieren
APA
Khan, M. D. F. H., Sudalaiyadum Perumal, A., & Kamen, A. A. (2026). Investigation on a Freeze-Drying Process for Long-Term Stability of mRNA-LNPs. Vaccines, 14(3), 242. https://doi.org/10.3390/vaccines14030242
Vancouver
Khan MDFH, Sudalaiyadum Perumal A, Kamen AA. Investigation on a Freeze-Drying Process for Long-Term Stability of mRNA-LNPs. Vaccines. 2026;14(3):242. doi:10.3390/vaccines14030242
BibTeX
@article{Khan2026,
author = {Khan, M D Faizul Hussain and Sudalaiyadum Perumal, Ayyappasamy and Kamen, Amine A},
title = {Investigation on a Freeze-Drying Process for Long-Term Stability of mRNA-LNPs},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {3},
pages = {242},
doi = {10.3390/vaccines14030242}
}
EUVIMED